SIOP CNS GCT 96: outcomes for children and adults with intracranial germinoma treated with radiotherapy alone or chemotherapy plus reduced radiotherapy
This large European trial showed that localised intracranial germinoma can be cured in almost every patient either with craniospinal radiotherapy or with chemotherapy followed by smaller-field radiotherapy, but that the reduced field must cover the ventricles to avoid relapse.
Overview
Prospective non-randomised trial of 235 patients with intracranial germinoma treated by choice with craniospinal irradiation (24 Gy plus boost) or two cycles of carboplatin, etoposide and ifosfamide followed by focal radiotherapy (40 Gy); metastatic disease received craniospinal irradiation.
Five-year event-free survival was 97 percent with craniospinal irradiation and 88 percent with the combined approach; relapses after focal radiotherapy occurred mainly in the ventricles, prompting whole-ventricular irradiation in the successor trial.
- Five-year event-free survival 97 percent with craniospinal irradiation vs 88 percent with chemotherapy and focal radiotherapy.
- Ventricular relapses after focal fields led to adoption of whole-ventricular irradiation.
Chemotherapy followed by whole-ventricular irradiation with a tumour boost, rather than craniospinal irradiation, is the standard for localised germinoma, sparing children the neurocognitive and endocrine cost of wider fields.
- Treatment was allocated by institutional preference rather than randomisation.
Similar pages
not linked directly; found by shared links- Key paperACNS1123: response-based reduced-dose whole-ventricular radiotherapy for localised germinoma
Shares Neuro-Oncology, Central nervous system germ cell tumours (germinoma and non-germinomatous).
- Key paperThe 2021 WHO classification of tumours of the central nervous system: a summary
Shares Neuro-Oncology, Central nervous system germ cell tumours (germinoma and non-germinomatous).